Evidence map›Paper›PMID 38315633›Full record

ArticleJournal of leukocyte biology2024

Tissue damage from chronic liver injury inhibits peripheral NK cell abundance and proinflammatory function.

Zonghao You, Shaoxue Ling, Shuwu Zhao, Haixing Han, Yuhong Bian, Yongzhi He, Xi Chen

Abstract read
In one paragraph

Article in Journal of leukocyte biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zonghao YouCollege of Pharmaceutical Engineering of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, P. R. China.
Shaoxue LingCollege of Pharmaceutical Engineering of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, P. R. China.
Shuwu ZhaoSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, P. R. China.
Haixing HanSINOSH (Tianjin) Group Co., Ltd, Tianjin, P. R. China.
Yuhong BianSchool of Integrative Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, P. R. China.ORCID 0000-0001-9192-787X
Yongzhi HeCollege of Pharmaceutical Engineering of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, P. R. China.
Xi ChenCollege of Pharmaceutical Engineering of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, P. R. China.

Funding

NIH HHS
6 · The paper itself

Abstract

One of the difficulties in the treatment of hepatocellular carcinoma is that it is impossible to eliminate the inhibitory effect of the tumor microenvironment on immune response. Therefore, it is particularly important to understand the formation process of the tumor microenvironment. Chronic inflammation is the core factor of cancer occurrence and the leading stage of inflammation-cancer transformation, and the natural killer cell subsets play an important role in it. Our study confirmed that in the stage of chronic liver injury, the local immunosuppressive microenvironment of the liver (i.e. the damaged microenvironment) has been formed, but this inhibitory effect is only for peripheral natural killer cells and has no effect on tissue-resident natural killer subsets. The markers of damage microenvironment are the same as those of tumor microenvironment.

Indexed as

InflammationKiller Cells, NaturalAnimalsChronic DiseaseHumansLiverMaleTumor Microenvironmentchronic liver injuryconventional NK cellshepatic carcinomainflammation-cancer transformationliver-resident NK cellstumor microenvironment

Identifiers

PMID38315633
PMCPMC11135618

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.